

Updates in regulating medical devices reimbursement

The Ministry of Health submitted a draft amendment to Act No 48/1997 Sb., on Public Health Insurance (the “PHI Act”), in response to the judgement of the Constitutional Court, ref. No. Pl. Ú S 3/15 of 30 May 2017 (the “Judgement”) that repealed the regulation of reimbursement of prescription medical devices.

Recap of the Judgement

In its Judgement, the Constitutional Court repealed the key provisions of the PHI Act governing the calculation of the payment for medical devices reimbursed from the public health insurance for out-patient services, which we covered in our Pharma Flash from June 2017 (available [here](#)). The Constitutional Court repealed the regulation of reimbursement of medical devices provided by prescription (e.g. incontinence pads, prosthetics, wheelchairs, hearing aids, glucometers and other aids for people with diabetes). The Court specifically repealed provisions stipulating that the insured are entitled to reimbursement of the most economical medical devices as determined by health insurance companies in a market survey.

The Ministry of Health has drafted an amendment to the Public Health Insurance Act. The bill reacts to the judgement of the Constitutional Court repealing, as of 1 January 2019, a section of the Act on the regulation of the reimbursement of prescription medical devices. Although the Constitutional Court noted that the regulation of reimbursement of medical devices used in hospital treatment (i.e. separately charged material) has the same defects, it did not repeal these provisions. The Ministry of Health failed to address this issue in its bill too.

As of 1 January 2019, Section C of Annex 3 of the PHI Act, containing the list of prescription medical devices reimbursed from the public health insurance, will therefore be virtually left blank. The aim of the proposed bill is to “ensure wide-ranging availability of fully reimbursed medical devices while minimising economic impacts on the public health insurance scheme”, according to the explanatory notes.

Changes envisaged by the bill

If adopted, the bill will introduce changes in the classification of reimbursed prescription medical devices and in the method of classification.

The mentioned Annex 3 will undergo the most crucial changes – it will be fully replaced. The new table that will replace the existing list of medical devices reimbursed from the public health insurance for out-patient services features a total of 7 classifications:

- classification tree
- description
- prescription limitations
- indication restrictions
- volume restrictions
- financial cap
- reusability

The new table is more detailed and specific, which should lead to simpler and more exact classification of devices into reimbursement categories. It is noteworthy that as opposed to the existing regulation, the financial cap for the reimbursement is not set as a percentage with a maximum amount in CZK but instead as a maximum amount in CZK per unit (ml, g, cm²).

We believe that specifically Annex 3 will be subject to an extensive debate and a number of adjustments during the law-making process before becoming final.

The classification method is also stipulated in great detail. The reimbursement of prescription medical devices will be based on the classification in the specific reimbursement category pursuant to Annex 3. The producer (or the authorised representative of a producer established in a third country, or a person authorised in writing by the producer or the authorised representative of the producer established in a third country), acting as the declarant, will electronically inform the State Institute for Drug Control (“SIDC”) on the classification, deletion or change of the medical device in the reimbursement category, or a category of principally interchangeable medical devices within the reimbursement

Pharma Flash

May 2018

category, if created by the SIDC. The declarant may request an opinion on the classification from the SIDC.

The SIDC can also decide to delete a medical device from a reimbursement category, e.g. in the case where the medical device has been placed in a category to which it does not belong, given its functional characteristics or the designated purpose or use.

Medical devices and aids reimbursed as at 31 December 2017 will be reimbursed starting from 1 January 2019 in the same amount as at 31 December 2017, until the date of publication of the new reimbursement amount. Medical devices reimbursed as at 31 December 2018, but not as at 31 December 2017, will be reimbursed starting from 1 January 2019 in the same amount as at 31 December 2018, until the date of publication of the new reimbursement amount.

For the sake of completeness, we should mention that the consultation stage has ended and the bill is currently back with the Ministry of Health. It is expected to be submitted

to the government's law-making council work groups, then to the government itself. In the best-case scenario, the first reading in the Chamber of Deputies could take place already this June.

Quo vadis, reimbursement regulation?

Interestingly, the Constitutional Court held that the regulation of reimbursement of medical devices used in hospital treatment (i.e. separately charged material) has the same defects as that relating to the reimbursement of prescription medical devices. Nonetheless, the Court did not repeal the provisions in question.


The bill submitted by the Ministry of Health therefore only addresses the changes in the area of prescription medical devices, not those used in hospital treatment. The question remains whether and when the regulation of the reimbursement of hospital medical devices will be amended.

Authors:

Václav Audes | Partner

Veronika Filipová | Associate

Eliška Toušková | Junior Associate



The most successful law firm in the Czech Republic and Slovakia based on the number of nominations and awards in all years of the competition



Ranked by clients as the Best Law Firm in the Czech Republic (2010, 2013, 2015)



Czech Law Firm of the Year (2011–2012, 2014–2017)



M&A Law Firm of the Year in the Czech Republic and Slovakia (2016)



No. 1 legal advisor according to the number of M&A deals in the Czech Republic



HAVEL & PARTNERS

CONNECTED THROUGH SUCCESS

Our team

200 lawyers | 400 employees

Our clients

1,000 clients | 70 of the Fortune 500 global companies
50 companies in the Czech Top 100 league | 7 companies in the Czech Top 10 league

International approach

Legal advice
in more than 80 countries of the world
in 12 world languages
up to 70% of cases involve an international element

www.havelpartners.cz

PRAGUE

Florentinum, Reception A
Na Florenci 2116/15
110 00 Prague 1
Czech Republic
Tel.: +420 255 000 111

BRNO

Titanium Business Complex
Nové sady 996/25
602 00 Brno
Czech Republic
Tel.: +420 545 423 420

OSTRAVA

Poděbradova 2738/16
702 00 Ostrava
Czech Republic
Tel.: +420 596 110 300

BRATISLAVA

Zuckerman del Centre
Žižkova 7803/9
811 02 Bratislava
Slovak Republic
Tel.: +421 232 113 900